These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 33882330)

  • 21. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.
    Maurer M; Rosén K; Hsieh HJ; Saini S; Grattan C; Gimenéz-Arnau A; Agarwal S; Doyle R; Canvin J; Kaplan A; Casale T
    N Engl J Med; 2013 Mar; 368(10):924-35. PubMed ID: 23432142
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Are age-specific high serum IgE levels associated with worse symptomatology in children with atopic dermatitis?
    Hon KL; Lam MC; Leung TF; Wong KY; Chow CM; Fok TF; Ng PC
    Int J Dermatol; 2007 Dec; 46(12):1258-62. PubMed ID: 18173519
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patient-reported outcomes in urticarial vasculitis treated with omalizumab: case report.
    Cherrez-Ojeda I; Vanegas E; Felix M; Mata VL; Cherrez A
    BMC Dermatol; 2018 Oct; 18(1):8. PubMed ID: 30359231
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients.
    Riccio AM; Dal Negro RW; Micheletto C; De Ferrari L; Folli C; Chiappori A; Canonica GW
    Int J Immunopathol Pharmacol; 2012; 25(2):475-84. PubMed ID: 22697079
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of omalizumab in a patient with hyper-IgE syndrome and review dermatologic manifestations.
    Chularojanamontri L; Wimoolchart S; Tuchinda P; Kulthanan K; Kiewjoy N
    Asian Pac J Allergy Immunol; 2009 Dec; 27(4):233-6. PubMed ID: 20232578
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Eosinophil-derived neurotoxin as a biomarker for disease severity and relapse in recalcitrant atopic dermatitis.
    Kim HS; Kim JH; Seo YM; Chun YH; Yoon JS; Kim HH; Lee JS; Kim JT
    Ann Allergy Asthma Immunol; 2017 Nov; 119(5):441-445. PubMed ID: 28866306
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.
    Jackson DJ; Humbert M; Hirsch I; Newbold P; Garcia Gil E
    Adv Ther; 2020 Feb; 37(2):718-729. PubMed ID: 31836949
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Corrigendum to 'IgE blockade in the management of eosinophil-associated recalcitrant pruritus due to medical tumor therapy': Annals of Oncology 2021; volume 32: 696-697.
    Gutzmer R; Sibaud V; Hassel JC
    Ann Oncol; 2021 Oct; 32(10):1310. PubMed ID: 34373158
    [No Abstract]   [Full Text] [Related]  

  • 29. Effect of omalizumab on biomarkers in middle ear effusion in patients with eosinophilic otitis media.
    Iino Y; Hara M; Hasegawa M; Matsuzawa S; Shinnabe A; Kanazawa H; Yoshida N
    Acta Otolaryngol; 2014 Apr; 134(4):366-72. PubMed ID: 24628335
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma.
    Noga O; Hanf G; Brachmann I; Klucken AC; Kleine-Tebbe J; Rosseau S; Kunkel G; Suttorp N; Seybold J
    J Allergy Clin Immunol; 2006 Jun; 117(6):1493-9. PubMed ID: 16751018
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IgE and eosinophils as therapeutic targets in asthma.
    Patel TR; Sur S
    Curr Opin Allergy Clin Immunol; 2017 Feb; 17(1):42-49. PubMed ID: 27906698
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful treatment of recalcitrant, erythroderma-associated pruritus with etanercept.
    Querfeld C; Guitart J; Kuzel TM; Rosen S
    Arch Dermatol; 2004 Dec; 140(12):1539-40. PubMed ID: 15611443
    [No Abstract]   [Full Text] [Related]  

  • 33. RANTES in exhaled breath condensate of patients with severe persistent allergic asthma during omalizumab therapy.
    Zietkowski Z; Skiepko R; Tomasiak-Lozowska MM; Lenczewska D; Bodzenta-Lukaszyk A
    Int Arch Allergy Immunol; 2011; 154(1):25-32. PubMed ID: 20664274
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors.
    Simon SCS; Hu X; Panten J; Grees M; Renders S; Thomas D; Weber R; Schulze TJ; Utikal J; Umansky V
    Oncoimmunology; 2020; 9(1):1727116. PubMed ID: 32117594
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Utility of serum periostin and free IgE levels in evaluating responsiveness to omalizumab in patients with severe asthma.
    Tajiri T; Matsumoto H; Gon Y; Ito R; Hashimoto S; Izuhara K; Suzukawa M; Ohta K; Ono J; Ohta S; Ito I; Oguma T; Inoue H; Iwata T; Kanemitsu Y; Nagasaki T; Niimi A; Mishima M
    Allergy; 2016 Oct; 71(10):1472-9. PubMed ID: 27113353
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IgE blockade in autoimmunity: Omalizumab induced remission of bullous pemphigoid.
    James T; Salman S; Stevenson B; Bundell C; Kelly G; Nolan D; John M
    Clin Immunol; 2019 Jan; 198():54-56. PubMed ID: 30557620
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation.
    Holgate S; Casale T; Wenzel S; Bousquet J; Deniz Y; Reisner C
    J Allergy Clin Immunol; 2005 Mar; 115(3):459-65. PubMed ID: 15753888
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunoglobulin E monitoring and reduction of omalizumab therapy in children and adolescents.
    Steiss JO; Schmidt A; Nährlich L; Zimmer KP; Rudloff S
    Allergy Asthma Proc; 2012; 33(1):77-81. PubMed ID: 22370532
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase.
    Maurer M; Altrichter S; Bieber T; Biedermann T; Bräutigam M; Seyfried S; Brehler R; Grabbe J; Hunzelmann N; Jakob T; Jung A; Kleine-Tebbe J; Mempel M; Meurer M; Reich K; Ruëff F; Schäkel K; Sengupta K; Sieder C; Simon JC; Wedi B; Zuberbier T; Mahler V; Staubach P
    J Allergy Clin Immunol; 2011 Jul; 128(1):202-209.e5. PubMed ID: 21636116
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Changes in blood eosinophilia during omalizumab therapy as a predictor of asthma exacerbation.
    Skiepko R; Ziętkowski Z; Lukaszyk M; Budny W; Skiepko U; Milewski R; Bodzenta-Łukaszyk A
    Postepy Dermatol Alergol; 2014 Oct; 31(5):305-9. PubMed ID: 25395927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.